869472-64-0Relevant articles and documents
SOLID FORMS OF APOL1 INHIBITOR AND METHODS OF USING SAME
-
Paragraph 0194-0195, (2021/08/13)
The disclosure provides novel solid state forms of Compound I selected from Form B, citric acid cocrystal Form A, piperazine cocrystal Form A, urea cocrystal Form A, nicotinamide cocrystal Form A, nicotinamide cocrystal Form B, aspartame cocrystal Form A, glutaric acid cocrystal Form A, L-proline cocrystal Form A, L-proline cocrystal Form B, vanillin cocrystal Form A, and 2-pyridone cocrystal Form A, compositions comprising the same, and methods of using the same, including use in treating APOL1 mediated kidney disease.
INHIBITORS OF APOL1 AND METHODS OF USING SAME
-
Paragraph 00407; 00411, (2020/07/14)
The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).